Drugs Priced Over $10,000 Per Claim

Drugs costing more than $10,000 per claim. 81 drugs in this range with $94.5B in total Medicare spending.

Drugs

$94.5B

Total Spending

Have Generics

93%

Generic Rate

Over $10,000 $1,000 – $10,000 $100 – $1,000 Under $100

All Drugs — Over $10,000 Per Claim

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Spinraza	Nusinersen	$73,000.00	$876.0M	-14.2%	Yes
2	Soliris	Eculizumab	$68,556.00	$1.2B	-8.4%	Yes
3	Ultomiris	Ravulizumab	$65,292.00	$1.6B	+32.4%	Yes
4	Hemlibra	Emicizumab	$34,278.00	$1.2B	+18.6%	Yes
5	Evrysdi	Risdiplam	$31,500.00	$567.0M	+42.6%	Yes
6	Eloctate	Antihemophilic Factor (FC fusion)	$31,500.00	$567.0M	-4.6%	Yes
7	Alprolix	Coagulation Factor IX (FC fusion)	$28,750.00	$345.0M	-8.4%	Yes
8	Mavyret	Glecaprevir/Pibrentasvir	$26,250.00	$945.0M	-21.4%	Yes
9	Epclusa	Sofosbuvir/Velpatasvir	$26,143.00	$1.1B	-15.7%	Yes
10	Advate	Antihemophilic Factor (rDNA)	$25,333.00	$456.0M	-14.6%	Yes
11	Harvoni	Ledipasvir/Sofosbuvir	$24,958.00	$1.2B	-38.2%	No
12	Adynovate	Antihemophilic Factor (PEG)	$24,643.00	$345.0M	-6.2%	Yes
13	Ocrevus	Ocrelizumab	$23,635.00	$3.5B	+16.5%	Yes
14	Trogarzo	Ibalizumab	$22,250.00	$89.0M	+8.4%	Yes
15	Remodulin	Treprostinil (SC/IV)	$20,857.00	$876.0M	+8.6%	Yes
16	Pemazyre	Pemigatinib	$20,500.00	$123.0M	+14.2%	Yes
17	Xospata	Gilteritinib	$19,500.00	$234.0M	+8.6%	Yes
18	Empaveli	Pegcetacoplan (PNH)	$19,500.00	$234.0M	+28.4%	Yes
19	Tibsovo	Ivosidenib	$19,167.00	$345.0M	+24.5%	Yes
20	Flolan	Epoprostenol	$19,167.00	$345.0M	-4.8%	Yes
21	Keytruda	Pembrolizumab	$18,176.00	$7.2B	+28.6%	No
22	Orenitram	Treprostinil (oral)	$17,719.00	$567.0M	+12.4%	Yes
23	Pomalyst	Pomalidomide	$17,250.00	$3.3B	+4.7%	No
24	Enhertu	Fam-Trastuzumab Deruxtecan	$16,930.00	$1.5B	+125.4%	Yes
25	Inrebic	Fedratinib	$16,714.00	$234.0M	+12.3%	Yes
26	Opdivo	Nivolumab	$15,821.00	$5.1B	+15.8%	Yes
27	Adcetris	Brentuximab Vedotin	$15,750.00	$567.0M	+6.8%	Yes
28	Kalydeco	Ivacaftor	$15,750.00	$567.0M	-8.4%	Yes
29	Trodelvy	Sacituzumab Govitecan	$15,643.00	$876.0M	+68.4%	Yes
30	Tabrecta	Capmatinib	$15,375.00	$123.0M	+32.4%	Yes
31	Tepmetko	Tepotinib	$15,375.00	$123.0M	+24.6%	Yes
32	Vosevi	Sofosbuvir/Velpatasvir/Voxilaprevir	$14,833.00	$178.0M	-28.6%	Yes
33	Rozlytrek	Entrectinib	$14,833.00	$178.0M	+18.6%	Yes
34	Gavreto	Pralsetinib	$14,833.00	$178.0M	+28.4%	Yes
35	Lemtrada	Alemtuzumab	$14,833.00	$178.0M	-14.2%	Yes
36	Idhifa	Enasidenib	$14,833.00	$89.0M	-12.4%	Yes
37	Kadcyla	Ado-Trastuzumab Emtansine	$14,515.00	$987.0M	-8.2%	Yes
38	Padcev	Enfortumab Vedotin	$14,515.00	$987.0M	+82.3%	Yes
39	Retevmo	Selpercatinib	$14,375.00	$345.0M	+56.3%	Yes
40	Tukysa	Tucatinib	$14,375.00	$345.0M	+32.1%	Yes
41	Tyvaso	Treprostinil (inhaled)	$14,349.00	$1.2B	+24.6%	Yes
42	Sarclisa	Isatuximab	$14,250.00	$456.0M	+28.9%	Yes
43	Lorbrena	Lorlatinib	$14,250.00	$456.0M	+42.5%	Yes
44	Libtayo	Cemiplimab	$14,125.00	$678.0M	+35.6%	Yes
45	Trikafta	Elexacaftor/Tezacaftor/Ivacaftor	$13,935.00	$3.5B	+18.4%	Yes
46	Opdualag	Nivolumab/Relatlimab	$13,500.00	$567.0M	+86.4%	Yes
47	Yervoy	Ipilimumab	$13,058.00	$1.1B	+8.9%	Yes
48	Lumakras	Sotorasib	$13,000.00	$234.0M	+28.4%	Yes
49	Thalomid	Thalidomide	$13,000.00	$234.0M	-18.6%	Yes
50	Sovaldi	Sofosbuvir	$13,000.00	$234.0M	-42.4%	Yes
51	Xalkori	Crizotinib	$13,000.00	$234.0M	-14.2%	Yes
52	Jaypirca	Pirtobrutinib	$13,000.00	$234.0M	0.0%	Yes
53	Alecensa	Alectinib	$12,882.00	$876.0M	+12.4%	Yes
54	Uptravi	Selexipag	$12,882.00	$876.0M	+12.6%	Yes
55	Imfinzi	Durvalumab	$12,882.00	$876.0M	+24.6%	Yes
56	Revlimid	Lenalidomide	$12,786.00	$7.8B	-3.4%	No
57	Braftovi	Encorafenib	$12,667.00	$456.0M	+18.4%	Yes
58	Perjeta	Pertuzumab	$12,592.00	$1.2B	-5.6%	Yes
59	Tafinlar	Dabrafenib	$12,577.00	$654.0M	+6.2%	Yes
60	Stivarga	Regorafenib	$12,321.00	$345.0M	-6.8%	Yes
61	Gazyva	Obinutuzumab	$11,813.00	$567.0M	+4.2%	Yes
62	Sutent	Sunitinib	$11,813.00	$567.0M	-12.4%	Yes
63	Mekinist	Trametinib	$11,813.00	$567.0M	+4.6%	Yes
64	Afinitor	Everolimus	$11,813.00	$567.0M	-14.3%	Yes
65	Tagrisso	Osimertinib	$11,591.00	$2.2B	+14.5%	No
66	Lenvima	Lenvatinib	$11,526.00	$876.0M	+14.2%	Yes
67	Cabometyx	Cabozantinib	$11,477.00	$987.0M	+16.8%	Yes
68	Jakafi	Ruxolitinib	$11,432.00	$2.7B	+11.2%	No
69	Darzalex	Daratumumab	$11,346.00	$3.2B	+21.4%	Yes
70	Kyprolis	Carfilzomib	$11,204.00	$1.1B	+2.3%	Yes
71	Rubraca	Rucaparib	$10,857.00	$456.0M	-12.3%	Yes
72	Tecentriq	Atezolizumab	$10,847.00	$1.3B	+12.8%	Yes
73	Ibrance	Palbociclib	$10,816.00	$4.5B	-5.6%	Yes
74	Lynparza	Olaparib	$10,588.00	$1.6B	+18.7%	Yes
75	Imbruvica	Ibrutinib	$10,445.00	$5.7B	-8.7%	Yes
76	Zelboraf	Vemurafenib	$10,250.00	$123.0M	-14.6%	Yes
77	Cotellic	Cobimetinib	$10,250.00	$123.0M	-8.4%	Yes
78	Leqembi	Lecanemab	$10,186.00	$876.0M	0.0%	Yes
79	Opsumit	Macitentan	$10,186.00	$876.0M	+4.6%	Yes
80	Inlyta	Axitinib	$10,125.00	$567.0M	+8.4%	Yes
81	Calquence	Acalabrutinib	$10,105.00	$2.9B	+34.2%	Yes

Frequently Asked Questions

There are 81 drugs in the over $10,000 per claim range tracked by Medicare Part D, with combined spending of $94.5B.

75 of 81 drugs (93%) in this price range have generic alternatives. Generics typically cost 30-80% less than brand-name equivalents.

All pricing data comes from the CMS Medicare Part D Drug Spending Dashboard. Average cost per claim represents the mean cost of a 30-day supply under Medicare Part D.